Recent Updates
Recently added Catalysts
LLY Positive Sentiment

Veeva Vault CRM Selected by Eli Lilly and Company

Key Takeaway: Eli Lilly and Company has selected Veeva Vault CRM for global implementation, enhancing its commercial model using AI technology. This strategic partnership aims to improve patient access to Lilly's innovative medicines. Veeva's CEO expressed pride in this collaboration, highlighting the potential benefits for both companies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eli Lilly is expanding its strategic partnership with Veeva.
  • Vault CRM aims to enhance patient access to breakthrough medicines.
  • The technology leverages AI for improved commercial operations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
2%
average across 15 past catalysts
Lead asset
LY2189265
Phase 1 · Diabetes Mellitus, Type II

Full Press Release Details

PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.
Vault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients.
"We are excited to expand our strategic work with Veeva by moving to Vault CRM," said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly. "Vault CRM will help Lilly bring our breakthrough medicines to more patients."
"Lilly creates medicines that make life better for people around the world," said Veeva CEO Peter Gassner. "We are proud to expand our strategic work with Lilly as they roll out Vault CRM globally."
Learn more about Veeva Vault CRM Suite, including the Agentic Call Report to generate Commercial Evidence, at veeva.com/crm.
About Veeva Systems Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Maria Scurry Veeva Systems [email protected] Meera Lakhani-Patel Veeva Systems, Europe [email protected]

Frequently Asked Questions

What is Veeva Vault CRM?

Veeva Vault CRM is a suite of applications designed to enhance commercial operations using AI.

Why did Eli Lilly choose Veeva Vault CRM?

Eli Lilly aims to improve patient access to its breakthrough medicines through the use of Vault CRM.

What benefits does Vault CRM provide?

Vault CRM helps streamline commercial processes and leverage AI for better patient engagement.

Who is the CEO of Veeva Systems?

Peter Gassner is the CEO of Veeva Systems.

Last updated: Aug 11, 2026